1 / 127

Comprehensive Guide to Ledipasvir-Sofosbuvir (Harvoni) Treatment

Learn about ledipasvir-sofosbuvir indications, dosing, adverse effects, clinical trials, and outcomes in HCV patients, with key study summaries and drug interactions.

jeanl
Download Presentation

Comprehensive Guide to Ledipasvir-Sofosbuvir (Harvoni) Treatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Ledipasvir-Sofosbuvir (Harvoni) Prepared by: David H. Spach, MD and H. Nina Kim, MD MSc Last Updated: December 15, 2015

  2. Ledipasvir-Sofosbuvir (Harvoni) Background and Dosing

  3. Ledipasvir-Sofosbuvir (Harvoni) • Approval Status- Initial approval by United States FDA October 10, 2014- Expanded indications approved by FDA November 12, 2015 • Indications and Usage - Indicated for the treatment of chronic HCV genotypes 1, 4, 5, and 6 in adults- Indicated for the treatment of chronic HCV in patients co-infected with HIV • Class & Mechanism- Ledipasvir: NS5A inhibitor- Sofosbuvir: Nucleotide analog NS5B polymerase inhibitor • Dosing: Ledipasvir-Sofosbuvir (fixed dose 90 mg/400 mg) One tablet orally once daily with or without food • Adverse Effects (AE): Fatigue, headache Source: Harvoni Prescribing Information. Gilead Sciences

  4. Ledipasvir-Sofosbuvir (Harvoni)Indications and Usage Source: Harvoni Prescribing Information. Gilead Sciences

  5. Ledipasvir-Sofosbuvir (Harvoni)Estimated Cost of Therapy

  6. Ledipasvir-Sofosbuvir(Harvoni)Drug-Drug Interactions • Not recommended for coadministration with:- P-gp inducers(eg. rifampin, St. John’s Wort)- Amiodarone • Consult Prescribing Information Regarding Interactions with: - Acid reducing agents- Antiarrhythmics- Anticonvulsants- Antimycobacterials- HIV antiretrovirals Source: Harvoni Prescribing Information. Gilead Sciences

  7. Ledipasvir-Sofosbuvir (Harvoni)Adverse Effects Source: Harvoni Prescribing Information. Gilead Sciences

  8. Clinical Trials Ledipasvir-Sofosbuvir

  9. Ledipasvir-Sofosbuvir (LDV-SOF): Summary of Key Studies • Treatment Naïve (Phase 3)- ION-1: GT-1 / LDV-SOF +/- RBV x 12 or 24 weeks- ION-3: GT-1 / LDV-SOF +/- RBV x 8 weeks vs LDV/SOF x 12 weeks • Treatment Naïve(Phase 2)- NIAID SYNERGY (GT-1): GT-1 LDV-SOF +/- [GS-9669 or GS-9451] • Treatment Experienced (Phase 3)- ION-2: GT-1 / LDV-SOF +/- RBV x 12 or 24 weeks • Treatment Experienced with Compensated Cirrhosis (Phase 2)- SIRIUS: GT-1 / LDV-SOF + RBV x 12 weeks or LSV-SOF x 24 weeks

  10. Ledipasvir-Sofosbuvir (LDV-SOF): Summary of Key Studies • Treatment Naïve or Treatment Experienced (Phase 2)- LONESTAR: GT-1 / LDV-SOF +/- RBV x 8 or 12 weeks- ELECTRON (Arms 12-17 & 22): LDV-SOF +/- RBV x 6 or 12 weeks- ELECTRON-2: experienced GT-1 & naïve GT-3/ LDV-SOF +/- RBV x 12 weeks- New Zealand: GT 3,6 / LDV-SOF +/- RBV x 12 weeks- NIAID SYNERGY (GT-4): GT 4 / LDV/SOF x 12 weeks • Prior Sofosbuvir Failure (Phase 2)- NIAID: GT-1 / LDV-SOF +/- RBV x 12 weeks- PRIOR Failure in Sofosbuvir Trials: GT-1 / LDV-SOF +/- RBV x 12 weeks

  11. Ledipasvir-Sofosbuvir (LDV-SOF): Summary of Key Studies • HIV Coinfection: Treatment Naïve (Phase 2)- NIAID ERADICATE: GT 1 / LDV-SOF x 12 weeks +/- HIV antiretrovirals • HIV Coinfection: Treatment Naïve or Treatment Experienced- ION-4: GT 1 or 4 / LDV-SOF x 12 weeks +/- HIV antiretrovirals • Advanced Liver Disease: Pre and Post Transplant (Phase 2)- SOLAR-1: GT 1,4 / LDV-SOF + RBV x 12 or 24 wks

  12. Ledipasvir-Sofosbuvir in Treatment-Naïve Patients

  13. Phase 3 TreatmentNaïve Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1ION-1 Afdhal N, et al. N Engl J Med. 2014;370:1889-98.

  14. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Naïve HCV GT 1ION-1 Study: Features Source: Afdhal N, et al. N Engl J Med. 2014;370:1889-98.

  15. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Naïve HCV GT 1ION-1 Study: Study Design 0 12 24 36 Week GT-1Naive n =214 SVR12 LDV-SOF n =217 SVR12 LDV-SOF + RBV n =217 SVR12 GT-1Naive LDV-SOF n =217 SVR12 LDV-SOF + RBV Abbreviations: LDV-SOF= ledipasvir-sofosbuvir; RBV = ribavirin Drug DosingLedipasvir-sofosbuvir (90/400 mg): fixed dose combination; one pill once dailyRibavirin (weight-based and divided bid): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg Source: Afdhal N, et al. N Engl J Med. 2014;370:1889-98.

  16. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Naïve HCV GT 1ION-1 Study: Baseline Characteristics Source: Afdhal N, et al. N Engl J Med. 2014;370:1889-98.

  17. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Naïve HCV GT 1ION-1 Study: Results ION-1: SVR 12* by Treatment Duration and Regimen 211/214 211/217 212/217 215/217 12-Week Regimen 24-Week Regimen Abbreviations: LDV-SOF= ledipasvir-sofosbuvir; RBV = ribavirin*Primary end-point by intention-to-treat analysis Source: Afdhal N, et al. N Engl J Med. 2014;370:1889-98.

  18. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Naïve HCV GT 1ION-1 Study: Results ION-1: SVR12 by Treatment Regimen and Liver Disease 179/179 32/33 178/178 33/33 181/182 31/32 179/179 36/36 12-Week Treatment 24-Week Treatment Note: subgroup results do not include patients who withdrew consent or were lost to follow-up Source: Afdhal N, et al. N Engl J Med. 2014;370:1889-98.

  19. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Naïve HCV GT 1ION-1 Study: Results for Ledipasvir-Sofosbuvir ION-1: SVR12 by Treatment Duration and Liver Disease 179/179 32/33 181/182 31/32 Source: Afdhal N, et al. N Engl J Med. 2014;370:1889-98.

  20. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Naïve HCV GT 1ION-1 Study: Resistance Data • NS5A resistant variants- Baseline resistance in 140 (16%) of 861 patients tested- SVR12 in 135 (96%) of 140 patients with NS5A resistance- 2 of the 3 patients with virologic failure had baseline NS5A resistance Source: Afdhal N, et al. N Engl J Med. 2014;370:1889-98.

  21. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Naïve HCV GT 1ION-1 Study: Conclusions Source: Afdhal N, et al. N Engl J Med. 2014;370:1889-98.

  22. Phase 3 TreatmentNaïve Ledipasvir-Sofosbuvir for 8 or 12 weeks in HCV GT1ION-3 Kowdley K, et al. N Engl J Med. 2014;370:1879-88.

  23. Ledipasvir-Sofosbuvir for 8 or 12 Weeks in Treatment-Naïve HCV GT 1ION-3 Study: Features Source: Kowdley, K, et al. N Engl J Med. 2014;370:1879-88.

  24. Ledipasvir-Sofosbuvir for 8 or 12 Weeks in Treatment-Naïve HCV GT 1ION-3 Study: Study Design 0 8 12 20 24 Week SVR12 n =215 GT-1 Naïve Non-cirrhotic LDV-SOF n =216 SVR12 LDV-SOF + RBV GT-1Naive n =216 SVR12 LDV-SOF Abbreviations: LDV= ledipasvir; SOF = sofosbuvir; RBV = ribavirin Drug DosingLedipasvir-sofosbuvir (90/400 mg): fixed dose combination; one pill once dailyRibavirin (weight-based and divided bid): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg Source: Kowdley, K, et al. N Engl J Med. 2014;370:1879-88.

  25. Ledipasvir-Sofosbuvir for 8 or 12 Weeks in Treatment-Naïve HCV GT 1ION-3 Study: Baseline Characteristics Source: Kowdley, K, et al. N Engl J Med. 2014;370:1879-88.

  26. Ledipasvir-Sofosbuvir for 8 or 12 Weeks in Treatment-Naïve HCV GT 1ION-3 Study: Results ION-3: SVR 12* by Treatment Duration and Regimen 201/216 206/216 202/215 8-Week Regimen 12-Week Regimen Abbreviations: LDV-SOF= ledipasvir-sofosbuvir; RBV = ribavirin*Primary end-point by intention-to-treat analysis Source: Kowdley, K, et al. N Engl J Med. 2014;370:1879-88.

  27. Ledipasvir-Sofosbuvir for 8 or 12 Weeks in Treatment-Naïve HCV GT 1ION-3 Study: Results Source: Harvoni Prescribing Information. Gilead Sciences

  28. Ledipasvir-Sofosbuvir for 8 or 12 Weeks in Treatment-Naïve HCV GT 1ION-3 Study: Resistance Data • NS5B S282T variant (reduces susceptibility to sofosbuvir) - Not observed in any patients at baseline or after treatment by deep sequencing • NS5A resistant variants- Baseline resistance in 116 (18%) of 647 patients- SVR12 in 104 (90%) of 116 patients with NS5A resistance- Of the 23 patients who had viral relapse, 15 (65%) had NS5A-resistant variants at time of relapse Source: Kowdley, K, et al. N Engl J Med. 2014;370:1879-88.

  29. Ledipasvir-Sofosbuvir for 8 or 12 Weeks in Treatment-Naïve HCV GT 1ION-3 Study: Conclusions Source: Kowdley, K, et al. N Engl J Med. 2014;370:1879-88.

  30. Title changed on results slide Phase 2 TreatmentNaïve (unfavorable baseline treatment characteristics) Ledipasvir-Sofosbuvir +/- 3rd DAA in HCV Genotype 1 NIAID SYNERGY: Genotype 1 KohliA, et al. Lancet. 2015:385:1107-13.

  31. Ledipasvir-Sofosbuvir +/- [GS-9669 or GS-9451] in Naïve GT1NIAID SYNERGY GT-1 Trial: Features Source: Kohli A, et al. Lancet. 2015:385:1107-13.

  32. Ledipasvir-Sofosbuvir +/- [GS-9669 or GS-9451] in Naïve GT1NIAID SYNERGY GT-1 Trial: Features 0 6 12 18 24 Week Treatment NaïveAll stages fibrosis LDV-SOF n =20 SVR12 Treatment NaïveCirrhosis excluded LDV-SOF+ GS-9669 n = 20 SVR12 Treatment NaïveCirrhosis excluded LDV-SOF + GS-9451 n = 20 SVR12 Abbreviations: LDV-SOF= ledipasvir-sofosbuvir Drug DosingLedipasvir-sofosbuvir (90/400 mg): fixed dose combination; one pill once dailyGS-9669: 500 mg once dailyGS-9451: 80 mg once daily Source: Kohli A, et al. Lancet. 2015:385:1107-13.

  33. Ledipasvir-Sofosbuvir +/- [GS-9669 or GS-9451] in Naïve GT1NIAID SYNERGY GT-1 Trial: Participants Source: Kohli A, et al. Lancet. 2015:385:1107-13.

  34. Ledipasvir-Sofosbuvir +/- [GS-9669 or GS-9451] in Naïve GT1NIAID SYNERGY GT-1 Trial: Viral Kinetics 7 Sofosbuvir + Ledipasvir 6 Sofosbuvir + Ledipasvir + GS-9669 Sofosbuvir + Ledipasvir + GS-9451 5 4 Log10 Median HCV RNA (IU/ml) 3 *p<0.05 *p<0.05 *p<0.05 2 0 7 14 21 28 Time (days) Source: Kohli A, et al. Lancet. 2015:385:1107-13.

  35. Ledipasvir-Sofosbuvir +/- [GS-9669 or GS-9451] in Naïve GT1NIAID SYNERGY GT-1 Trial: Results NIH SYNERGY: SVR 12 by Treatment Regimen 20/20 19/20* 19/20^ *1 patient relapsed 2 weeks after completion of treatment^1 patient lost to follow-up after reaching SVR at 4 weeks Source: Kohli A, et al. Lancet. 2015:385:1107-13.

  36. Ledipasvir-Sofosbuvir +/- [GS-9669 or GS-9451] in Naïve GT1NIAID SYNERGY GT-1 Trial: Interpretation Source: Kohli A, et al. Lancet. 2015:385:1107-13.

  37. Ledipasvir-Sofosbuvir in Treatment-Experienced Patients

  38. Phase 3 TreatmentExperienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93.

  39. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV GT 1ION-2 Study: Features Source: Afdhal N, et al. N Engl J Med. 2014;370:1483-93.

  40. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV GT 1ION-2 Study: Study Design 0 12 24 36 Week GT-1Experienced n =109 SVR12 LDV-SOF n =111 SVR12 LDV-SOF + RBV GT-1Experienced n =109 SVR12 LDV-SOF n =111 SVR12 LDV-SOF + RBV Abbreviations: LDV= ledipasvir; SOF = sofosbuvir; RBV = ribavirin Drug DosingLedipasvir-sofosbuvir (90/400 mg): fixed dose combination; one pill once dailyRibavirin (weight-based and divided bid): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg N =14 Source: Afdhal N, et al. N Engl J Med. 2014;370:1483-93.

  41. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV GT 1ION-2 Study: Baseline Characteristics Source: Afdhal N, et al. N Engl J Med. 2014;370:1483-93.

  42. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-experienced HCV GT 1ION-2 Study: Results ION-2: SVR 12* by Treatment Duration and Regimen 102/109 107/111 108/109 110/111 12-Week Regimen 24-Week Regimen Abbreviations: LDV-SOF= ledipasvir-sofosbuvir; RBV = ribavirin*Primary end-point by intention-to-treat analysis Source: Afdhal N, et al. N Engl J Med. 2014;370:1483-93.

  43. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-experienced HCV GT 1ION-2 Study: Results ION-2: SVR12 by Treatment Regimen and Liver Disease 83/87 19/22 89/89 18/22 86/87 22/22 88/89 22/22 12-Week Treatment 24-Week Treatment Source: Afdhal N, et al. N Engl J Med. 2014;370:1483-93.

  44. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-experienced HCV GT 1ION-2 Study: Results for Ledipasvir-Sofosbuvir ION-2: SVR12 by Treatment Regimen and Liver Disease 83/87 19/22 86/87 22/22 Note: subgroup results do not include patients who withdrew consent or were lost to follow-up Source: Afdhal N, et al. N Engl J Med. 2014;370:1483-93.

  45. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-experienced HCV GT 1ION-2 Study: Results ION-2: SVR12 by Prior Treatment Regimen 40/43 62/66 45/47 62/64 58/58 49/50 58/59 51/51 12-Week Treatment 24-Week Treatment Source: Afdhal N, et al. N Engl J Med. 2014;370:1483-93.

  46. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-experienced HCV GT 1ION-2 Study: Resistance Data • NS5B S282T variant (reduces susceptibility to sofosbuvir) - Not observed in any patients at baseline or after treatment • NS5A resistant variants- Baseline resistance in 62 (14%) of 439 patients tested- SVR12 in 55 (89%) of 62 patients with NS5A resistance- All 11 patients who had viral relapse had detectable NS5Aresistant variants at the time of relapse • NS3/4A resistant variants- Baseline resistance in 163 (71%) of 228 patients tested- SVR12 in 159 (98%) of 163 patients with resistance Source: Afdhal N, et al. N Engl J Med. 2014;370:1483-93.

  47. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV GT 1ION-2 Study: Conclusions Source: Afdhal N, et al. N Engl J Med. 2014;370:1483-93.

  48. Phase 2 TreatmentExperienced Ledipasvir-Sofosbuvir in Treatment-Experienced GT1 with Cirrhosis SIRIUS Bourliere M, et al. Lancet Infect Dis. 2015;15:397-404.

  49. Ledipasvir-Sofosbuvir in Treatment-Experienced GT1 with Cirrhosis SIRIUS Trial: Features Source: BourliereM, et al. Lancet Infect Dis. 2015;15:397-404.

  50. Ledipasvir-Sofosbuvir in Treatment-Experienced GT1 with Cirrhosis SIRIUS Trial: Study Design 0 12 24 36 Week n =77 Placebo LDV-SOF + RBV SVR12 n =78 LDV-SOF SVR12 Drug DosingLedipasvir-sofosbuvir (90/400 mg): fixed dose combination; one pill once dailyRibavirin (weight-based and divided bid): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg N =14 Abbreviations: LDV= ledipasvir; SOF = sofosbuvir; RBV = ribavirin Source: BourliereM, et al. Lancet Infect Dis. 2015;15:397-404.

More Related